One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Opthea Limited logo
Opthea Limited OPT
report update icon

Quarterly report 2025-Q2
added 05-16-2026

Opthea Limited Income Statement 2025-2011 | OPT

Brief overview of financial performance at Opthea Limited

This overview is based on financial performance over the past five years. The revenue attributed to Opthea Limited moved from 59.1 thousand dollars to 25 thousand dollars between the two endpoints. The five-year change reached −57.7%, while CAGR stood at −15.8%. Sales followed a declining trajectory over the five years.

The operating result measured by EBITDA moved from 0 dollars to −156 million dollars, or . EBITDA margin was 0% at the start and −623048% at the end. The margin contraction indicates weaker operating efficiency.

The net financial result changed from −$11.1 million to −$163 million. The period ended with a larger loss than it began with.

Conclusion

The indicators point to a weaker financial profile. The most visible risks are a declining EBITDA margin, weak sales momentum and a narrow EBITDA buffer. Further direction will depend on top-line growth, operating profitability, and net income.

Annual Income Statement Opthea Limited

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- - - 2.11 B 2.24 B 2.87 B - 277 K 3.63 M 207 K 150 K 4.1 M 1.93 M 3.51 M 40.2 M

Shares

1.22 B 638 M 443 M 352 M 320 M 261 M - 25.2 M 20.2 M 18.8 M 13.6 M 6.22 M 6.21 M 5.95 M 5.91 M

Historical Prices

- - - 6 7.54 11.2 - - - - - - - - -

Net Income

-163 M -220 M -143 M -92.8 M -45.3 M -11.1 M -20.9 M -16.9 M -6.19 M -6.51 M -5.31 M -4 M -4.75 M -4.84 M -10.3 M

Revenue

25 K 125 K 108 K 90.7 K 68.6 K 59.1 K - - - - - - - - -

Operating Income

-156 M -192 M -150 M -96.5 M - - - - - - - - - - -

Interest Expense

46.5 M 30.3 M 13.5 M - - - - - - - - - - - -

EBITDA

-156 M -192 M -150 M -96.5 M - - -36.9 M -29.9 M -9.87 M -8.05 M -9.35 M -7.57 M -8.13 M -9.18 M -11.9 M

Operating Expenses

156 M 192 M 150 M 96.7 M - - - - - - - - - - -

General and Administrative Expenses

- - - - - - 4.68 M 3.08 M 2.97 M 2.61 M 2.36 M 1.69 M 2.17 M 2.44 M 2.52 M

All numbers in USD currency

Quarterly Income Statement Opthea Limited

2025-Q2 2024-Q2 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

1.22 B 638 M 443 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-163 M -220 M -143 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

25 K 125 K 108 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-156 M -192 M -150 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

46.5 M 30.3 M 13.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-156 M -192 M -150 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

156 M 192 M 150 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Opthea Limited (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Annexon Annexon
ANNX
$ 4.2 -0.71 % $ 651 M usaUSA
AbbVie AbbVie
ABBV
$ 293.87 0.19 % $ 520 B usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 151.6 -3.2 % $ 19.9 B usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 4.63 21.05 % $ 20 M israelIsrael
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 302.6 -0.19 % $ 23.6 B usaUSA
Theratechnologies Theratechnologies
THTX
- - $ 83.9 M canadaCanada
Liquidia Corporation Liquidia Corporation
LQDA
$ 51.37 7.31 % $ 4.42 B usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 45.05 -9.97 % $ 4.05 B schweizSchweiz
Scholar Rock Holding Corporation Scholar Rock Holding Corporation
SRRK
$ 48.48 -5.96 % $ 5.56 B usaUSA
Geron Corporation Geron Corporation
GERN
$ 0.96 -3.71 % $ 640 M usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 62.8 1.06 % $ 128 B usaUSA
Titan Pharmaceuticals Titan Pharmaceuticals
TTNP
- -3.76 % $ 3.47 M usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
$ 7.4 -0.13 % $ 113 M australiaAustralia
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 30.68 -1.81 % $ 2.04 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 4.0 -6.76 % $ 48.8 M israelIsrael
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
$ 317.26 0.99 % $ 6.14 B usaUSA
Eli Lilly and Company Eli Lilly and Company
LLY
$ 1 432.7 1.47 % $ 1.29 T usaUSA
TCR2 Therapeutics TCR2 Therapeutics
TCRR
- - $ 58.1 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
TFF Pharmaceuticals TFF Pharmaceuticals
TFFP
- -60.05 % $ 125 K usaUSA
Mesoblast Limited Mesoblast Limited
MESO
$ 14.0 -3.06 % $ 16.9 B australiaAustralia
CorMedix CorMedix
CRMD
$ 5.37 -2.1 % $ 387 K usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
MannKind Corporation MannKind Corporation
MNKD
$ 4.22 0.84 % $ 1.29 B usaUSA
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
MediciNova MediciNova
MNOV
$ 1.4 -4.76 % $ 68.7 M usaUSA
Merck & Co. Merck & Co.
MRK
$ 147.75 -0.68 % $ 370 B usaUSA
Moderna Moderna
MRNA
$ 250.79 -6.77 % $ 97.6 B usaUSA
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
Intellia Therapeutics Intellia Therapeutics
NTLA
$ 11.18 -7.72 % $ 1.21 B usaUSA
Novartis AG Novartis AG
NVS
$ 163.39 -0.18 % $ 317 B schweizSchweiz
Omeros Corporation Omeros Corporation
OMER
$ 17.3 -1.48 % $ 1.1 B usaUSA
Oramed Pharmaceuticals Oramed Pharmaceuticals
ORMP
$ 3.97 -0.75 % $ 164 M israelIsrael
Tyme Technologies Tyme Technologies
TYME
- 8.07 % $ 54 M usaUSA
Puma Biotechnology Puma Biotechnology
PBYI
$ 8.13 -3.22 % $ 407 M usaUSA
PDS Biotechnology Corporation PDS Biotechnology Corporation
PDSB
$ 1.02 -5.09 % $ 47.3 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
$ 34.99 3.77 % $ 147 M usaUSA
Pfizer Pfizer
PFE
$ 29.34 0.36 % $ 167 B usaUSA
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
PainReform Ltd. PainReform Ltd.
PRFX
$ 0.78 -4.24 % $ 505 K israelIsrael
Prothena Corporation plc Prothena Corporation plc
PRTA
$ 8.56 -2.51 % $ 461 M usaUSA
Arcus Biosciences Arcus Biosciences
RCUS
$ 18.66 -1.56 % $ 2 B usaUSA
Orgenesis Orgenesis
ORGS
- -33.86 % $ 61.2 M usaUSA
Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Limited
RDY
$ 14.9 -1.03 % $ 12.4 B indiaIndia
Regeneron Pharmaceuticals Regeneron Pharmaceuticals
REGN
$ 916.16 -0.41 % $ 95.8 B usaUSA
Replimune Group Replimune Group
REPL
$ 23.3 4.67 % $ 2.16 B usaUSA
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia